• N,N'-Dicyclohexylurea (DCU): sEH Overview

  2026-10-16

  A source-limited overview of N,N'-Dicyclohexylurea (DCU), covering its documented identity, supplier-described inhibition of soluble epoxide hydrolase, the interpretation of biochemical and downstream readouts, and the boundaries created by the absence of an identity-matched research paper.

• Risperidone: Mechanism and Evidence Boundaries

  2026-10-16

  APExBIO describes Risperidone CAS 106266-06-2 as a small-molecule antagonist with reported affinity for 5-HT2A and D2 receptors. Those product-level data establish chemical identity and a proposed pharmacological target profile, but they do not independently demonstrate receptor signaling effects, disease mechanisms, or outcomes in schizophrenia research.

• Pemetrexed: Mechanism, Scope, and Evidence Limits

  2026-10-15

  A source-attributed overview of Pemetrexed and pemetrexed disodium as a multi-targeted antifolate, distinguishing the product description’s mechanistic claims from downstream antiproliferative observations and identifying the limits created by the absence of an identity-matched primary study.

• Methoxy-X04: Interpreting a Fluorescent Amyloid Probe

  2026-10-15

  APExBIO describes Methoxy-X04 as a brain-permeable fluorescent amyloid beta probe for detecting Aβ fibrils, oligomeric species, plaques, and cerebrovascular amyloid. The available evidence is product-level rather than an identity-matched research publication, so its claims support a conceptual measurement overview but not independent conclusions about performance, disease mechanisms, or clinical applicability.

• STING agonist-1: Evidence and Scope

  2026-10-14

  STING agonist-1 is an APExBIO-listed small molecule described as a STING-pathway agonist and type I interferon activator. The available evidence establishes catalog identity, stated properties, and intended research scope, but does not provide identity-matched study data on potency, selectivity, target engagement, or disease-model outcomes.

• ROS-Responsive mRNA Delivery: Evidence and Limits

  2026-10-14

  A source-grounded overview of a 2022 proof-of-concept study on ROS-degradable lipid nanoparticles for tumor-cell-selective mRNA delivery, with emphasis on what the findings establish, what remains uncertain, and why a Cy5 RNA labeling kit represents a separate analytical context.

• MnTBAP and Stress-Linked Brain Dysfunction

  2026-10-13

  A rat study links chronic unpredictable mild stress with altered mitochondrial function, inflammatory signaling, and depression-like behavior. MnTBAP reduced behavioral abnormalities in that model, but the findings remain preclinical and do not establish clinical efficacy, target specificity, or applicability beyond the experimental system.

• PPM-18: Evidence Boundaries in NF-κB Research

  2026-10-13

  PPM-18 is a synthetic naphthoquinone derivative described by APExBIO as an inhibitor of NF-κB-linked inducible nitric oxide synthase expression. The available supplier evidence suggests anti-inflammatory activity in cellular and rodent endotoxemia models, but the supplied osteology study concerns oridonin rather than PPM-18. Its findings therefore provide pathway context, not direct validation, and do not establish clinical efficacy or broad applicability.

• A Cartilage Organoid Model for Hypertrophy

  2026-10-12

  Wang and colleagues describe a human expanded pluripotent stem cell model that follows cartilage development through a sclerotome intermediate and three-dimensional maturation. The reported findings support its use as a developmental research platform, while the supplied record does not establish clinical relevance, broad reproducibility, or the effects of Y-27632 dihydrochloride in this system.

• Pemetrexed Research Context in Mesothelioma

  2026-10-12

  Borchert et al. investigated homologous-recombination defects and PARP-inhibitor sensitivity in malignant pleural mesothelioma models. The study provides hypothesis-generating evidence about BAP1-associated treatment responses, but it does not establish clinical efficacy for pemetrexed-based or PARP-inhibitor combinations.

• Isoliensinine and Microglial MAPK/NF-κB Signaling

  2026-10-10

  Yuan et al. (2025) investigate how isoliensinine affects LPS-induced inflammation in BV2 microglial cells, linking MAPK/NF-κB modulation with reduced oxidative stress, mitochondrial dysfunction, and improved neuronal cell viability in a conditioned-media model. The findings provide a cell-based mechanistic rationale for further neuroinflammation research, while remaining preliminary because they do not establish efficacy in animal models or patients.

• ARID1A-Driven Resistance in Melanoma: Multi-Omics

  2026-10-09

  This study integrates multi-omics data to explain how ARID1A loss rewires early signaling and supports resistance to BRAF/MAPK inhibition in melanoma. Its identification of PRKD1, JUN, and NCK1 as resistance-associated network nodes offers mechanistic hypotheses for cancer biology and metastatic melanoma research, while remaining limited by its model-based evidence scope.

• BRCAness and Olaparib Sensitivity in Mesothelioma

  2026-10-09

  Borchert et al. linked homologous recombination repair gene-expression patterns with olaparib sensitivity in malignant pleural mesothelioma models, with particular evidence in BAP1-mutated cells. The study supports biomarker-guided investigation of PARP inhibition, but its in vitro design and exploratory clinical-sample analysis limit direct clinical interpretation.

• Vemurafenib and Resistance in Melanoma Research

  2026-10-08

  A source-grounded overview of Vemurafenib (PLX4032, RG7204) as a research perturbation in BRAF-mutant melanoma, with emphasis on MAPK biology, ARID1A-associated resistance, multi-omics interpretation, evidence strength, and applicability limits.

• Aztreonam: Research Context, Findings, and Limits

  2026-10-08

  A source-grounded overview of Aztreonam as a monocyclic β-lactam antibiotic, covering its conceptual role in Gram-negative research, supplied findings on progenitor cells and liver cytochrome P450 enzymes, comparison with a large cefiderocol susceptibility study, and key evidence limitations.

8699 records 1/580 page Next 12345 下5页 Last page